RE:RE:Simply Wall Street determines ONCY fair value at $157 p/sAnd at no time in the past 24 years has ONCY been ready to move towards a registration study with pelareorep in combination with a biomarker in multiple cancer indications. Over this time ONCY has been able to demonstrate that pelareorep induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
We are now awaiting for ONCY to confirm efficacy data and additional biomarker analyses from the yet-to-be-fully-reported BRACELET-1 mBC Phase 2 clinical trial that Big Pharma is expected to take into a Phase 3/4 registration/post-marketing confirmation study.